Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Variable regions on heavy and light chains of antihuman IL-13R alpha 2 monoclonal antibodies

A monoclonal antibody and variable region technology, applied in the field of biomedicine, can solve the problems of low affinity and large dosage of humanized antibodies

Inactive Publication Date: 2009-11-25
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In the process of constructing humanized antibodies, the humanized antibodies obtained by using technologies such as phage antibody library have low affinity, and the dosage is large

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Variable regions on heavy and light chains of antihuman IL-13R alpha 2 monoclonal antibodies
  • Variable regions on heavy and light chains of antihuman IL-13R alpha 2 monoclonal antibodies
  • Variable regions on heavy and light chains of antihuman IL-13R alpha 2 monoclonal antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The present invention will be described in detail below.

[0018] The complete nucleotide sequence of the variable region gene, especially the nucleotide sequence of its functional fragments (such as CDR, etc.) and the amino acid sequence of the antibody variable region, are chimeric antibodies, single-chain antibodies or humanized antibody construction Foundation. To this end, the applicant immunized BALB / c mice with recombinant human IL-13Rα2, prepared a group of mouse anti-human IL-13Rα2 monoclonal antibodies, cloned and screened FMMU that can secrete high-affinity human IL-13Rα2 monoclonal antibodies - IL-13Rα2-7 hybridoma cell line, the hybridoma cell line has the ability of stably secreting antibody.

[0019] Clone the monoclonal antibody light chain and heavy chain variable region genes; the monoclonal antibody variable region gene sequences are shown in SEQ ID NO.3 and SEQ ID NO.4; obtain the monoclonal antibody light chain and heavy chain Chain variable regio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses variable regions on heavy and light chains of antihuman IL-13R alpha 2 monoclonal antibodies. Recombinant human IL-13R alpha 2 is used for immunizing a BALB / c mouse to prepare a group of mouse antihuman IL-13R alpha 2 monoclonal antibodies; and an IL-13R alpha 2 monoclonal antibody FMMU- IL-13R alpha 2-7 with high-affinity is selected. The genes in variable regions on heavy and light chains of the monoclonal antibody are cloned to obtain the gene sequences and the amino acid sequences of the variable regions on heavy and light chains of the monoclonal antibody; and the uniqueness of the gene sequences and protein sequences is confirmed. The amino acid sequences of the variable regions and the gene sequences encoding the variable regions have significant potential application values in the construction of IL-13R alpha 2-targeted single chain antibodies, chimeric antibodies, humanized antibodies or vaccines for treating malignant tumors.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, relates to a monoclonal antibody, in particular to a heavy chain and light chain variable region of an anti-human IL-13Rα2 monoclonal antibody (FMMU-IL-13Rα2-7), including its amino acid sequence and its nucleotide sequence. Background technique [0002] Malignant tumors are major diseases that endanger human health, and the treatment methods for them are still in the research and exploration stage. Following the traditional surgical treatment, radiotherapy, chemotherapy and immunotherapy, targeted antibody drug therapy represented by the combination of genetic engineering and protein engineering technology is becoming an emerging research field for the treatment of tumors. widespread attention. [0003] Human IL-13Rα2 is a tumor-specific marker highly expressed on the surface of malignant tumor cells such as human glioma, head and neck cancer, ovarian cancer and kidney cancer, and plays an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/24A61K39/395A61P35/00
Inventor 金伯泉陈丽华宋朝君龚玖瑜徐竹蔚杨琨
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com